Across 3 studies, all reported beneficial effects on gut microbiota composition, with effect sizes ranging from small to moderate. One statistically significant finding showed BB-12 increased beneficial Ligilactobacillus and decreased Bilophila in mice with acute pancreatitis. The evidence base is very small and preliminary.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. One study is a review, one is an in vitro model, and one is an animal study; no human trials are included. Doses, forms, study durations, and sample sizes are largely unreported, limiting interpretability. The overwhelming beneficial direction may be influenced by publication bias.
probiotics offer a simpler alternative to reinforce epithelial barrier function, restore cellular homeostasis, mitigate allergy symptoms
This was achieved through a significant rise in short-chain fatty acid (SCFA)-producing bacteria ... a rise in fecal SCFAs, and a reduction in harmful bacteria such as Escherichia.
both synbiotic treatments reduced Klebsiella spp., a potentially pathogenic genus
BB-12 treatment significantly increased the relative abundance of Ligilactobacillus and decreased that of Bilophila in the gut microbiota of mice with AP.
BB-12 conferred protection on the gut microbiota composition of the rats by increasing the abundance of Prevotella and decreasing the abundance of Clostridium, Blautia, and Bacteroides in 0-3 weeks... after a long-term intervention, BB-12 ameliorates obesity by enriching beneficial bacteria in the gut.